SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Analysis (n=8474) found effects of empagliflozin & dapagliflozin on hospitalisations for heart failure were consistent in the trials & suggest they also improve renal outcomes and reduce all-cause & CV death, irrespective of diabetes status or treatment with neprilysin inhibitor.

The Lancet